Kairos Pharma, LTD. Uncategorized Contracts & Agreements
6 Contracts & Agreements
- Conversion Agreement, dated March 7, 2024, between Cedars-Sinai Medical Center, Kairos Pharma, Ltd. and Enviro Therapeutics, Inc (Filed With SEC on May 1, 2024)
- Form of Director Offer Letter (Filed With SEC on September 29, 2023)
- Amendment to Exclusive Option Agreement between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. dated January 9, 2021 (re Sensitization of Solid Tumors) (Filed With SEC on September 29, 2023)
- Exclusive Option Agreement between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. dated March 16, 2020 (re Sensitization of Solid Tumors) (Filed With SEC on September 29, 2023)
- Amendment to Exclusive Option Agreement between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. dated January 11, 2021 (re Depletion of Mitochondrial DNA) (Filed With SEC on September 29, 2023)
- Exclusive Option Agreement between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. dated March 16, 2020 (re Depletion of Mitochondrial DNA) (Filed With SEC on September 29, 2023)